Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results

Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open‐label, phase 2 study (NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndromes (MDS). Patients received glasdegib 100 mg orally, once dail...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Cortes, Jorge E., Douglas Smith, B., Wang, Eunice S., Merchant, Akil, Oehler, Vivian G., Arellano, Martha, DeAngelo, Daniel J., Pollyea, Daniel A., Sekeres, Mikkael A., Robak, Tadeusz, Ma, Weidong Wendy, Zeremski, Mirjana, Naveed Shaik, M., Douglas Laird, A., O'Connell, Ashleigh, Chan, Geoffrey, Schroeder, Mark A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6221102/
https://ncbi.nlm.nih.gov/pubmed/30074259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25238
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados